Detalles de la búsqueda
1.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging;
2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
2.
Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
Eur J Nucl Med Mol Imaging;
46(11): 2270-2279, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31324943
3.
Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
BMC Cancer;
19(1): 134, 2019 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30744591
4.
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Eur J Nucl Med Mol Imaging;
43(10): 1792-801, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27072811
5.
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Eur J Nucl Med Mol Imaging;
42(8): 1304-14, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25792453
6.
Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study.
Diagnostics (Basel);
14(7)2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611625
7.
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
NPJ Breast Cancer;
10(1): 4, 2024 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38184611
8.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med;
65(5): 708-713, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575192
9.
Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
Clin Nucl Med;
48(9): 775-780, 2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37385221
10.
Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
J Nucl Med;
63(4): 549-555, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34326124
11.
Radiomics software comparison using digital phantom and patient data: IBSI-compliance does not guarantee concordance of feature values.
Biomed Phys Eng Express;
8(6)2022 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049399
12.
Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation.
Phys Med;
103: 138-146, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36308999
13.
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
NPJ Breast Cancer;
7(1): 125, 2021 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34548493
14.
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.
Clin Colorectal Cancer;
20(4): 326-333, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34404621
15.
Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer.
EJNMMI Phys;
7(1): 75, 2020 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33315160
16.
Fat density is a novel prognostic marker in patients with esophageal cancer.
Clin Nutr ESPEN;
39: 124-130, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32859305
17.
Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial.
Cancers (Basel);
12(10)2020 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32987838
18.
Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CTderived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer
J Nucl Med;
60(2): 178-184, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29959212
19.
Combining 18F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer.
J Nucl Med;
60(10): 1366-1372, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30850494
20.
A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours.
Phys Med;
56: 41-49, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30527088